Baker Tilly Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,693	Closed	-$459K	–	307
2024 Q1	$459K	Sell	1,693 -11	-0.6%	-$2.63K	0.08%	275
2023 Q4	$403K	Sell	1,704 -57	-3%	-$11.2K	0.07%	335
2023 Q3	$345K	Sell	1,761 -112	-6%	-$23K	0.06%	340
2023 Q2	$394K	Buy	1,873 +154	+9%	+$30.6K	0.04%	398
2023 Q1	$347K	Buy	1,719 +139	+9%	+$31.5K	0.04%	420
2022 Q4	$344K	Sell	1,580 -97	-6%	-$21.2K	0.04%	409
2022 Q3	$330K	Sell	1,677 -48	-3%	-$10.4K	0.05%	396
2022 Q2	$369K	Sell	1,725 -30	-2%	-$7.33K	0.05%	375
2022 Q1	$498K	Buy	1,755 +1	+0.1%	+$308	0.06%	346
2021 Q4	$661K	Buy	1,754 +82	+5%	+$31.9K	0.07%	299
2021 Q3	$690K	Buy	1,672 +91	+6%	+$37.8K	0.09%	248
2021 Q2	$585K	Buy	1,581 +325	+26%	+$109K	0.09%	241
2021 Q1	$364K	Buy	1,256 +228	+22%	+$63.4K	0.07%	309
2020 Q4	$257K	Buy	+1,028	New	+$245K	0.08%	272